RI Roadshow @National Cancer Centre Singapore
May 9th 2024, Thursday, 2-4pm NCCS Level 18 (Meeting Room 18-1 & 18-2)
National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease
NanoString Technologies, Inc. (OTC: NSTGQ), a leading provider of life science tools for discovery and translational research, today announced that research using the company’s CosMx™ Spatial Molecular Imager (SMI) has…
CST Chief Scientific Officer Roberto Polakiewicz Receives CiteAb Significant Individual Impact Award for Contributions to Scientific Rigor in Antibody Development
Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced that it was recognized in three categories in the 2024 CiteAb…
BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics
BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell…
Oxford Nanopore launches PromethION 2 Integrated into open early access
Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range. Engineered with robust…
Quanterix Granted Breakthrough Device Designation From U.S. FDA For Blood-Based P-Tau 217 Test For Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation…